P3H1 as a novel prognostic biomarker correlates with immune infiltrate

Abstract

Abstract Background Prolyl 3-hydroxylase 1(P3H1), a member of the collagen prolyl hydroxylase family, plays an important role in the development and progression of malignant tumors. However, expression and prognostic value of P3H1 and its correlation with tumor immunity in some cancer remain unclear. Methods We identified transcription level in the P3H1 gene by searching the GEPIA2.0 and ULCAN databases, and then analyzed the relationship between gene expression and prognosis in each tumor using survival R package, and computed the log-rank P value and hazard ratio (HR) with 95% confidence intervals (95% CI). Specifically, we used the oncomine and databases to further explore the relationship between P3H1 expression and the cancer prognosis. Moreover, we further investigated the role of P3H1 in tumor immunology using TIMER2.0 database. The relationship between the expression of this gene and TMB, NEO and MSI were also evaluated. More importantly, we performed signaling pathway enrichment analysis by KEGG and GO. Then, anticancer drug sensitivity analysis was performed using the pRRophetic R package. Finally, ELISA analysis was performed to compare the P3H1 serum level both the patients of COAD and healthy subjects. Results P3H1 was abnormally overexpressed in multiply tumors and distinct associations exist between P3H1 expression and prognosis of tumor patients by analysis online data. Moreover, we identified a strong correlation between P3H1 expression and immune checkpoint gene expression in diverse cancers. High expression of P3H1 was correlated with the immune infiltrated in COAD. Remarkably, a positive correlation between P3H1 expression and tumor mutation burden and neoantigen in colon adenocarcinoma (COAD) was observed. Furthermore, P3H1 was involved in the extracellular matrix organization and immune-related pathways in COAD. In addition, drug sensitivity analysis revealed that high P3H1 group has higher sensitivity in diverse drug for the therapy of COAD compared to low P3H1 group. Finally, the serum level of P3H1 was much higher in patients with COAD than in control subjects, indicating a link between P3H1 and COAD. Conclusion Our study provides a comprehensive insight for revealing the significant role of P3H1 in the expression, survival, tumor immune, microenvironment of human cancers, and anticancer drug sensitivity analysis of COAD.